Search Results for 'Ldl Cholesterol'

Ldl Cholesterol published presentations and documents on DocSlides.

Abnormalities of LDL metabolism
Abnormalities of LDL metabolism
by briana-ranney
Physiology, pathophysiology and treatments. Under...
Looking to FOURIER:  What do the trials tell us about LDL lowering and cardiovascular events?
Looking to FOURIER: What do the trials tell us about LDL lowering and cardiovascular events?
by min-jolicoeur
NICE –CG 181 Continuum of CVD Risk and its trea...
LDL is causal of atherosclerosis
LDL is causal of atherosclerosis
by morgan
Evidence from . meta-analyses of . Mendelian. . r...
PCSK9 Inhibition: LDL Lowering
PCSK9 Inhibition: LDL Lowering
by SweetiePie
PCSK9 inhibitors. New option for dyslipidemia. Ali...
Protecting the heart and the kidney:
Protecting the heart and the kidney:
by marina-yarberry
Implications from the SHARP trial. Dr. Christina ...
0 Circulation and Gas Exchange
0 Circulation and Gas Exchange
by tatyana-admore
The fluid that moves around in the circulatory sy...
Familial Hypercholesterolemia
Familial Hypercholesterolemia
by pasty-toler
Developed by . Ms. . Shawna . Morrison, Dr. Judit...
협심증  ( 狹心症 )
협심증 ( 狹心症 )
by lois-ondreau
Kyung Woo Park, MD, PhD, MBA . Seoul National Uni...
Triglycerides and Risk for Atherothrombosis
Triglycerides and Risk for Atherothrombosis
by briana-ranney
Thomas Dayspring, MD, FACP. Clinical Assistant Pr...
FOURIER F urther cardiovascular
FOURIER F urther cardiovascular
by trish-goza
OU. tcomes. . R. esearch with PCSK9 . I. nhibiti...
Risk factors in  heart disease
Risk factors in heart disease
by faustina-dinatale
Optimizing . patient care. William Cromwell, MD, ...
Long-term Tolerability and Efficacy of Evolocumab (AMG 145) in
Long-term Tolerability and Efficacy of Evolocumab (AMG 145) in
by pamella-moone
Hyperlipidemic. Subjects: A 52 Week Phase 3 Dou...
Update:  Lipid Guidelines
Update: Lipid Guidelines
by yoshiko-marsland
DO NOT BURN THE COOKIES. Amy R. Woods, M.D.. a. ...
New developments in lipid management
New developments in lipid management
by pasty-toler
CGR 0800 h 11 May 2015. Rob Hegele MD FRCPC FACP....
Trial Design Evolocumab SC
Trial Design Evolocumab SC
by danika-pritchard
140 mg Q2W or 420 mg QM. Placebo SC. Q2W or QM. L...
PCSK-9 Inhibitors Paul J
PCSK-9 Inhibitors Paul J
by tatyana-admore
PCSK-9 Inhibitors Paul J Kovack , DO, FACC, FACO...
 Diabetes and Dyslipidemia
Diabetes and Dyslipidemia
by danika-pritchard
2013 ACC/AHA Guideline on the. Treatment of Blood...
Protecting the heart and the kidney:
Protecting the heart and the kidney:
by pressio
Implications from the SHARP trial. Dr. Christina R...
Rational Order of Laboratory Tests in Cardiovascular Diseases
Rational Order of Laboratory Tests in Cardiovascular Diseases
by carneos
Sedighe. . S. adat . Ghorashi. . MD. Family Medic...
Oxidized- Low Density Lipoprotein Level Among Organophosphates (OPs)
Oxidized- Low Density Lipoprotein Level Among Organophosphates (OPs)
by mediumgeneral
Pesticide Exposed Workers. Nor Zamzila Abdullah. ...
DYSLIPIDEMIA IN DIABETES
DYSLIPIDEMIA IN DIABETES
by esther
MAHTAB NIROOMAND M.D.. Assistant professor of End...
Statin Side effects   Active treatment
Statin Side effects   Active treatment
by ximena
Control. Relative risk. Absolute Effect. (per thou...
ODYSSEY FH I and II In FH I:
ODYSSEY FH I and II In FH I:
by Aquamarine
From baseline to 24 weeks, the change in . LDL-C: ...
6701 Carnegie Ave  Suite 500  Cleveland OH 44103  p 8663589828
6701 Carnegie Ave Suite 500 Cleveland OH 44103 p 8663589828
by gelbero
ApoE genotype can affect:Response to treatment wit...
The role of cholesteryl ester transfer protein TaqIB polymorphism in y
The role of cholesteryl ester transfer protein TaqIB polymorphism in y
by sophie
Bilal Ilanbey Meral Kayikcioglu Ebru Demirel Sez...
CLINICAL PRACTICE
CLINICAL PRACTICE
by mia
USTRALIAN FAMILY Vol. 37, No. 7, July 2008 ichard ...
CLEVELAND CLINIC JOURNAL OF MEDICINE      VOLUME 73  NUMBER 1       J
CLEVELAND CLINIC JOURNAL OF MEDICINE VOLUME 73 NUMBER 1 J
by iris
CHRISTOPHER SIBLEY,MDDepartment of Cardiology,John...
SocietyPositionStatementCanadianCardiovascularSocietyPositionStatement
SocietyPositionStatementCanadianCardiovascularSocietyPositionStatement
by elizabeth
CanadianJournalofCardiology34(2018)1553 Receivedfo...
New concepts and guidelines in the management of LDL-c and CV Risk:
New concepts and guidelines in the management of LDL-c and CV Risk:
by cappi
Need for early intervention. Prof. . Ulf . Landmes...
Putting Your Skills to the Test
Putting Your Skills to the Test
by deborah
Which ONE of the following statements regarding th...
Non-obese rheumatoid arthritis patients
Non-obese rheumatoid arthritis patients
by valerie
withlow. low-density lipoprotein have higher coro...
Update on Clinical Trials:
Update on Clinical Trials:
by adia
How Will This Affect Practice in the Future?. Pame...
SWL lipid management guideline update- Highlights
SWL lipid management guideline update- Highlights
by finley
 . Pedro Bandeira. Specialist Pharmacist- Cardiov...
High Energy Physics Libraries Webzine Issue   November  httplibrary
High Energy Physics Libraries Webzine Issue November httplibrary
by marina-yarberry
cernchHEPLW5papers5 LDL Landscape Digital Library ...
Pediatric Obesity  and Metabolic Syndrome
Pediatric Obesity and Metabolic Syndrome
by cheryl-pisano
Chhavi Agarwal, MD, FAAP, MRCP (UK). Assistant Pr...
The results of the SHARP trial
The results of the SHARP trial
by stefany-barnette
SHARP: Rationale. Risk of vascular events is high...
Fatty Acid Synthesis
Fatty Acid Synthesis
by yoshiko-marsland
Chapter 28, . Stryer. Short Course. Lipoprotein ...
On-Treatment
On-Treatment
by lois-ondreau
Analysis. A Multicenter, Double-Blind, Randomized...